explore -WSS

explore

author：knowledge 2025-09-07 14:13:01 - browse：6767

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： 'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

WSS

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Astronauts get first look at the spacecraft that will fly them around the moon

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Hospitals use virtual reality to design more inclusive rooms for kids

Sage's campaign to raise awareness of postpartum depression hits a nerve

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

leisure time

explore

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Wegovy cuts risk of cardiovascular events by 20%, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Judge rejects Trump's counterclaim against E. Jean Carroll

Duchenne breakthrough therapy leaves behind pioneering families

Majority of Americans think Trump's Ga. election interference case is serious: POLL

In age of alternative facts, a scholarly course on calling out crap

ActiGraph execs on goal of drug approvals with digital endpoints

Dobbs anniversary: the lost opportunity of abortion as health care

Evacuations in place as 3 wildfires burn in eastern Washington state

hotspot

FTX founder Sam Bankman

FDA approves first treatment for ultra

Trump's false claims about Georgia's 2020 election long debunked

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Trump's false claims about Georgia's 2020 election long debunked

FTX founder Sam Bankman

focus

entertainment

knowledge

hotspot